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Inﬂammatory bowel diseaseBackground: There are no rapid tests that can distinguish contagious gastroenteritis, which requires iso-
lation at its onset, from exacerbation of chronic inﬂammatory bowel disease (IBD) or bowel engagement
in the course of systemic inﬂammatory response syndrome (SIRS). Hepatocyte growth factor (HGF) is an
acute phase cytokine that is produced at the site of injury. It has high afﬁnity to sulfated glycan, and this
binding afﬁnity is lost during chronic inﬂammation. The fecal pH strongly impacts the prognosis for
severe bowel disease. We developed a strip test to evaluate HGF as a local acute phase response marker
in the bowel. This test assessed the binding afﬁnity of HGF to sulfated glycans in fecal samples and deter-
mined fecal pH as an indicator of illness severity.
Methods: Fresh feces from patients with diarrhea (n = 513) were collected and tested blindly, and infor-
mation about patient illness course and outcome was collected. Patients were classiﬁed based on the
focus of inﬂammation and the cause of the symptoms. Objectively veriﬁed diagnoses of infectious gastro-
enteritis (n = 131) and IBD onset/exacerbation and bowel cancer (n = 44) were used to estimate the per-
formance of the test strip. ELISA was performed on 101 freeze-thawed feces samples to determine the
fecal HGF levels.
Results: The test rapidly distinguished infectious gastroenteritis from non-infectious inﬂammatory
causes of diarrhea (sensitivity, 87.96%; speciﬁcity, 90.9%; positive predictive value, 96.6%; negative pre-
dictive value, 71.4%; accuracy, 89.1%). Fecal pH (p < 0.0001) and mortality within 28 days of sampling
(p < 0.04) was higher in patients with sepsis/SIRS and diarrhea. The concentration of HGF was higher
in strip test-positive stool samples (p < 0.01).
Conclusions: HGF is a good local acute phase response marker of acute bowel inﬂammation. Test-strip
determination of the binding afﬁnity of fecal HGF to sulfated glycan was a rapid, equipment-free way
to assess patients with diarrhea and to guide the diagnostic and therapeutic approaches on admission.
 2014 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/3.0/).1. Introduction for a few serious diseases that include diarrhea as an initial symp-In order to inhibit disease transmission, patients with diarrhea
are isolated at medical centers upon admission. Based on the
patient’s medical and epidemiological history, a wide range of tests
and examinations may be performed before a deﬁnite diagnosis is
made [1]. Subsequent treatment may include ﬂuid and electrolyte
replacement plus antibiotic treatment for patients with fever and
stomach pain. However, appropriate treatment can be delayedtom. Such conditions include the onset of inﬂammatory bowel dis-
ease (IBD) in young patients, colon cancer (which has varying
periods of culture-negative diarrhea), and abdominal processes or
abscess that cause reactive diarrhea [2]. Despite the growing
problem of multidrug-resistant gram-negative bacteria, it is inap-
propriate to treat self-limiting infectious gastroenteritis with
broad-spectrum antibiotics, but this is quite common in medical
centers [3,4]. Various microbiological and immunological tests
are performed on stool samples when patients with diarrhea are
admitted to the hospital. However, these tests have limited sensi-
tivity with respect to antibiotic consumption and/or low antigen
burdens [5,6].
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cells during organ injury. It stimulates cell division [7] and cell
motility [8] and promotes normal morphogenic structure [9] in
epithelial cells adjacent to injured areas. It also induces the regen-
eration and repair of damaged tissue [10]. HGF is translated as a
single-chain precursor and is activated at the site of injury by pro-
teolytic cleavage, resulting in a double-chained active form of HGF
[11]. High levels of systemic HGF have been detected during inju-
ries caused by infection [12]. In bacterial meningitis and pneumo-
nia, there is local production of HGF at the site of infection [13,14].
To identify the bowel as the focus of inﬂammation, proteins and
cytokines that are produced locally at the site of injury can be
detected in feces. HGF is produced both systemically and locally
in infectious diseases [15–18], and determination of the HGF con-
centration in feces can be used to identify infectious gastroenteri-
tis. However, there may also be high levels of HGF in feces due to
chronic bowel diseases such as colon cancer and inﬂammatory
bowel disease (IBD) [19,20], limiting the speciﬁcity of such a test.
Furthermore, HGF produced during acute inﬂammation binds to
heparan sulfate proteoglycan (HSPG) with high afﬁnity but exhib-
its decreased afﬁnity to HSPG when produced during chronic
inﬂammation [21–26]. Based on these observations, we developed
a metachromatic semi-quantitative test to detect the presence of
growth factors such as HGF that show afﬁnity to sulfated glycans
in feces during infectious gastroenteritis [27].
Determination of fecal pH is a classic method for evaluating
signs of malnutrition and infection in feces. Recently, the pH levels
in the feces of severely ill patients were found to indicate the
severity of a disease or increased mortality [28].
In order to conﬁrm the results from previous studies [24], we
developed a platform that could be used to evaluate whether the
determination of substances with binding afﬁnity to sulfated gly-
cans, such as HSPG, could be used to distinguish between the var-
ious causes of diarrhea when patients with diarrhea were
admitted to the hospital. Dextran sulfate (DS) has properties sim-
ilar to those of HSPG in terms of binding to HGF [21]. We devel-
oped a new strip test that has two assay surfaces, one for
measuring fecal pH and one for detecting the binding afﬁnity of
fecal HGF to DS.
In the present work, we performed a cohort study in which we
assessed patients with symptoms of diarrhea and noted the out-
comes during follow-up of up to one year. We evaluated local pro-
duction of HGF as a local acute phase response marker in the bowel
using the newly developed strip test and determined whether use
of the test strip could distinguish infectious gastroenteritis versus
onset/exacerbation of IBD and bowel cancer in these patients.2. Patients and methods
2.1. Study population
A total of 513 fecal samples were collected in a blinded fashion
from patients with bowel disturbances who contacted health care
centers or hospital-connected home health care agencies, or who
were admitted to the University Hospital in Linköping or to county
hospitals in Norrköping and Motala, Sweden, from March 2012–
December 2013. Each patient was followed for up to one year after
inclusion in this study. Patients in hospital wards were isolated
until they recovered from diarrhea.
2.2. Sample collection and processing
– The stool samples included in this study were collected in
feces collecting tubes without additives (feces tube
#80.734, Sarstedt, Nümbrecht, Germany).– The samples were coded at collection and all identifying
information was removed.
– The samples were then sent to project staff members for
testing using the new strip test while the physician in
charge performed diagnostic procedures and oversaw
treatment.
– The strip tests results for each sample were documented in
the project database.
2.3. The new strip test
2.3.1. Description
– The new strip test for feces samples has two sensing sur-
faces (pads). The upper sensing surface detects the pres-
ence of HGF protein in the feces based on its binding
afﬁnity to DS, while the lower sensing surface determines
fecal pH (Fig. 1).
– A positive signal for the presence of HGF indicates an
infection or acute inﬂammation, while a negative response
could indicate chronic inﬂammation. The pH measure-
ment provides additional information that can help make
a diagnosis. For example, high fecal pH, i.e. pH 9–10, indi-
cates a generalized inﬂammatory response, bacterial
translocation, and septicemia.
2.3.2. Strip test pH assay results
– Stool samples were stored at room temperature for 15 min
prior to analysis.
– For analysis, a micro brush (Amax Medical Dental Supply
Ltd., Calgary, Canada) was soaked in deionized sterile
Milli-Q (MQ) water and immersed in the feces for 10 s.
– The micro brush was wiped twice on each of the two strip
pads.
– Fecal pH was determined by the pH sensor included in the
strip. The pH was indicated by the color of the strip, which
has a range from pH 4 to pH 10 (Fig. 1).
– The color change was observed within 60 s of application
of the sample to the strip and was compared to the CMYK
color chart [29] (Fig. 1).
2.3.3. Quality control and reproducibility of the new strip test
– Ten samples were analyzed 10 times with different
batches of strips in order to determine method variability
due to possible variations in strip preparation.
– Twenty strips from each batch (n = 5) were also tested
with negative controls (MQ water) and positive controls
(Recombinant HGF Standard, R&D Systems, Minneapolis,
MN, USA). The control tests were run daily prior to the
analysis of samples.
– All fecal samples were analyzed in duplicate with the same
results.
2.3.4. Concentration of HGF in feces
– Due to differences in fecal shape and consistency, it was
not possible to perform ELISA analysis on fresh samples.
The method used to standardize the volume of fecal sam-
ples was described previously [30].
– Fecal samples were collected and stored at 20 C within
24 h of collection.
– Prior to handling, the samples were thawed at room tem-
perature and mixed by vortexing. The narrow heads were
cut off of plastic syringes (2-ml, latex-free Omniﬁx
Fig. 1. The CMYK color chart for semi-quantitative evaluation of the presence of hepatocyte growth factor (HGF) in the bowel and for determining fecal pH. The strip on the
left (N) is negative for HGF and shows a fecal pH of 5–6. The strip on the right (P) is positive for HGF and shows a fecal pH of 8–9.
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The plunger of each syringe was pulled out to create a
small cylinder with an exact volume. The cylinder was
ﬁlled with the fecal sample and incubated at 70 C for
15 min, then kept at room temperature for 1 min. The
plunger of the syringe was then pushed down to empty
the cylinder into a 20-ml scintillation vial (Sarstedt AB,
Landskrona, Sweden) and diluted 1:6 with distilled water.
The sample was then vortexed, centrifuged at 3000g for
15 min, and the supernatant transferred to new tubes
(Nunc CryoTubes; Nunc Brand Products, Soeborg, Den-
mark). The supernatant was stored at 70 C until
analysis.
– For analysis, the supernatant samples were thawed and
centrifuged at 1000g for 15 min. Immunoreactive HGF lev-
els were determined by ELISA using a commercially avail-
able kit (Quantikine HGF Immunoassay, R&D Systems)
according to the manufacturer’s instructions. The mini-
mum detection level for the assay was 0.02 lg/L for feces.
2.4. Reference tests
Stool samples were analyzed using the following routine tests
at the Department of Microbiology, University Hospital in Linkö-
ping, Sweden:
1. Detection of Clostridium difﬁcile (C. difﬁcile) toxin A and B:
these toxins were detected using two-step sandwich enzy-
matic immunoanalysis with ﬂuorescent detection (auto-
mated ELFA-based VIDAS system; Biomerieux, Marcy
l’Etoile, France).
2. Isolation of C. difﬁcile from fecal specimens: stool samples
were collected using sterile copan eswabs (Copan Italia
S.P.A. via Perotti, Brescia, Italy) and inoculated on CCFE
agar (Lab. 090 agar for fastidious anaerobes; LAB-M, Lan-
cashire, UK) supplemented with cycloserine, cefoxitin,
and fructose.
3. Isolation of Salmonella, Shigella, and Campylobacter: stool
samples were collected using sterile copan eswabs and
cultured on xylose lysine deoxycholate agar (XLD) (Lab.
032 agar, LAB-M, Heywood, UK) and blood agar (Colombia
blood agar, Acumedia, Michigan, USA) and incubated in a
5% CO2 incubator.
4. Detection of Enterohemorrhagic Escherichia coli (EHEC):
stool samples were collected using sterile copan eswabs
and analyzed by PCR (Bio-Robot EZ1 advanced XL system,
Qiagen, Hilden, Germany) to detect EHEC.
5. Detection of viral agentsa. Detection of Calicivirus RNA: stool samples were col-
lected in feces collecting tubes without additives and
analyzed by PCR (Bio-Robot M 48 QIA-symphony sys-
tem, Qiagen) to detect Calicivirus RNA.
b. Detection of Rotavirus antigen: stool samples were col-
lected in feces collecting tubes without additives and
analyzed by Enzyme Immunoassay (EIA) (ProSpecT
rotavirus, Thermo Scientiﬁc, Waltham, MA, USA) to
detect the rotavirus antigen.
6. Detection of stool parasites: stool samples were collected in
ParasiTrap BIOSEPAR tubes (Biosepar GmbH, Germany)
containing formaldehyde-free ﬁxation and transport med-
ium and examined by light microscopy to detect stool
parasites.
7. Detection of fecal hemoglobin: qualitative analysis was per-
formed to detect fecal hemoglobin using antibodies devel-
oped against human hemoglobin (Fecal Immunochemical
test (FIT); OC FIT-CHEK, Polymedco. Inc. NY, USA).
8. Other tests: Other X-ray and endoscopic techniques were
used as indicated.
2.5. Database entry
– The project leader examined the medical records and the
medical history of each patient, and patient research ﬁles
were updated daily to include the results of routine labo-
ratory tests, X-rays, endoscopic procedures, and the ﬁnal
diagnosis before patient discharge.
– Patients were tracked for one year after inclusion in this
study to determine the ultimate diagnosis and outcome.
– In addition to the documentation in the research database,
the results of 74 cases were documented immediately in
the digital patient journal, COSMIC.
2.6. Statistical analysis
– GraphPad Prism Version 5 was used for statistical analysis.
– The speciﬁcity, sensitivity, and positive and negative pre-
dictive values of the new strip test were calculated
manually.
– Logistic regression was used to analyze correlations
between the results of the new strip test and the fecal
hemoglobin results.
– The Kruskal–Wallis and Mann–Whitney U tests were used
to analyze differences in fecal pH between the groups as
the data was not normally distributed, and the chi-square
test was used for analyzing mortality in the groups. The pH
Table 1
Ultimate diagnoses in the cohort of Swedish patients with diarrhea studied between March 2012 and December 2013.
Survey of patients
with diarrhea (n = 513)
Age range years (median age) –
females; in-patient
Etiological characteristics Microbiological test in feces
(result), further diagnostic
procedures
Positive fecal
strip test n,
(%)
Veriﬁed infection, non-IBD
n = 131
21–100 (73)-65; 101 Bacteria n = 101 Virus n = 27 Parasite
n = 3
(Positive) 117 (89.31%)
E. coli n = 1
C. difﬁcile n = 81 Rota virus n = 8
Salmonella n = 9 Calici virus
n = 19Campylobacter
n = 10
Veriﬁed infection, developed
IBD (n = 2)
23–44 (nd)-1; 2 Salmonella n = 2 (Positive), endoscopies,
bowel biopsies
0 (0%)
C. difﬁcile (clinically veriﬁed)
n = 40
30–90 (76)-16; 27 Previously positive toxin, diarrhea
treated efﬁciently with metronidazole/
oral vancomycin
(Negative) 36 (90%)
Short non-recurrent episode
< 2 weeks n = 97
3–100 (75)-54; 54 (median
9 days)
Positive epidemiology, unclear etiology (Negative) 74 (76.3%)
Sepsis/SIRS n = 66 29–102 (67)-35; 66 Severe colitis n = 13 (Negative) 59 (86.4%)
Septicemia n = 18
Severe pneumonia n = 8
Abdominal emergencies n = 16
Neutropen fever n = 11
Chronic diarrhea > 2 weeks
n = 36
21–93 (66)-21; 12 Depression, IBS, non-veriﬁed IBD,
constipation
(Negative) 6 (16.7%)
IBD n = 38 18–77 (42)-24; 8 Exacerbation n = 32 (Negative), endoscopies,
bowel biopsies
4 (10.5%)
Onset n = 6
Onset of malignancy n = 6 64–88 (74)-4; 3 Colon cancer n = 4 (Negative), endoscopies,
bowel biopsies
0 (0%)
Ventricle cancer n = 1
Lymphoma terminal ileum n = 1
Side-effect medicine n = 20 28–98 (71)- 9; 17 Carbapenem, PT, rifampycin,
trimetoprim n = 7
(Negative) 0 (0%)
Warfarin, adalimumab n = 2
Metformin, simvastatin, morﬁn n = 3
Photopheresis, anti epileptic n = 3
Nutrition n = 5
Other infectious foci n = 35 25–92 (78)-19; 27 Urinary tract infection n = 11 (Negative), other cultures
yielded
growth accordingly
4 (11.4%)
Lung inﬂammation n = 6
Focal infections/abscess n = 16
Fungemia n = 2
Other disturbances n = 18 38–95 (79)-12; 15 Abdominal bleeding (Negative) 2 (10.5%)
Uremia and electrolyte disorders
Terminal phase cancer patients
Liver diseases
Resolved symptom, no
recurrence n = 24
41–92 (69)-9; 12 Formed feces C. difﬁcile = 6 0 (0%)
Campylobacter = 1
Calici virus = 1
Blastocystis = 1
IBS inﬂammatory bowel syndrome; nd non-deﬁned; PT piperacillin–tazobactam.
A.E. Sorour et al. / Cytokine 71 (2015) 8–15 11is reported as a mean value with 95% CI, and mortality is
reported as a %. In this study, p 6 0.05 was considered sta-
tistically signiﬁcant.
– The Mann–Whitney U test was used to assess the signiﬁ-
cance of differences between fecal HGF concentrations
and the strip test results.
2.7. Ethics committee approval
The ethics committee in Linköping, Sweden, approved the study
protocol (M151-09, 2010/284-32).2.8. External review
The SP Technical Research Institute of Sweden studied the test
results and the ultimate patient outcomes to evaluate the sensitiv-
ity of the test (report designation 3P03321).3. Results
3.1. Diarrhea and differential diagnoses in randomly selected cases
over a one-year period
Acute infectious gastroenteritis was veriﬁed in 131 of the 513
fecal samples that were included in this study. In patients who
had negative microbiological test results, the differential diagnosis
was assessed by evaluating the course of treatment and the out-
come during the 1-year follow-up. Several sub-groups were identi-
ﬁed that are described in Table 1 and Fig. 2.3.2. Estimates of strip test performance
Patients with microbiologically veriﬁed infectious gastroenteri-
tis (n = 131) were compared to veriﬁed cases of IBD exacerbation/
onset (n = 38) and gastrointestinal malignancy (n = 6). The strip
test distinguished infectious gastroenteritis with a sensitivity of
Fig. 2. The study population of patients presenting with diarrhea.
12 A.E. Sorour et al. / Cytokine 71 (2015) 8–1587.9%, a speciﬁcity of 90.9%, a positive predictive value (PPV) of
96.6%, and a negative predictive value (NPV) of 71.4% (Table 2).
The reference test for C. difﬁcile toxins A and B identiﬁed cases with
recurrent enteritis with a sensitivity of 66.6% versus 90.9% using
the strip test (Table 1).
There was no signiﬁcant correlation between the strip test
results and the presence of blood in feces in the same sample
(n = 36, R2 = 0.07). Additionally, no signiﬁcant differences were
detected in the strip test results obtained from the same versus dif-
ferent batches of the strips.
3.3. Fecal pH and mortality within the ﬁrst month of sampling in
groups
Fecal pH was measured and documented in patients with loose
feces at the time of sampling. The patients were followed-up and
divided into groups based on laboratory and clinical outcome.
The sub-group with short non-recurrent episodes of diarrhea
(<2 weeks; n = 97; Table 1) was omitted because no further inves-
tigation was needed during the follow-up period to deﬁne the
cause of the short-term episode of diarrhea. The other cases con-
sisted of three major groups: (1) microbiologically- and clini-
cally-veriﬁed infectious gastroenteritis (n = 171; 10 patients died
2–26 days after admission and a median of 19 days after sampling,
mean fecal pH 7.0–8.0); (2) non-infectious cases (n = 178; 12patients died 1–30 days after admission and a median of 11 days
after sampling, mean fecal pH 5.0–6.0); and (3) cases with a gener-
alized inﬂammatory response (sepsis/SIRS; n = 66; 11 patients died
1–27 days after admission and a median of 6 days after sampling,
mean fecal pH 9.0–10.0). The groups were then compared
(p < 0.0001 for differences in pH and p < 0.04 for differences in
mortality between the groups; Fig. 3, Table 1).3.4. Fecal HGF concentration
The HGF concentration was measured by ELISA in 101 feces
samples. Of these 101, 49 were positive using the strip test and
52 were negative using the strip test. The HGF levels were signiﬁ-
cantly higher in the positive test group (p = 0.003; Table 3).4. Discussion
High levels of HGF are produced both locally and systemically in
injuries caused by infection [3]. Low levels of serum HGF in
patients with pneumonia correlates signiﬁcantly with poor prog-
nosis [31], and application of HGF to the site of an injury, such as
to the site of a chronic ulcer, accelerates the healing process [32].
The gastrointestinal mucosa has a remarkable ability to repair dam-
age, and growth factors play an important role in the regeneration
Table 2
The sensitivity and speciﬁcity of the strip test for distinguishing between infectious gastroenteritis and chronic inﬂammatory bowel disease (IBD).
Strip test result Infectious diarrhea All subgroups Non-infectious diarrhea All subgroups Total
Microbiologically veriﬁed as infectious Veriﬁed chronic inﬂammation
Bacteria Virus Parasite Suspected onset of IBD Onset of IBD Exacerbation of IBD Malignancy
Salmonella
Positive 91 23 3 0 117 0 4 0 4 121
Negative 10 4 0 2 16 6 28 6 40 56
Total 101 27 3 2 133 6 32 6 44 177
The test strip sensitivity was 87.96% and the speciﬁcity was 90.9%. The positive predictive value was 96.6%, and the negative predictive value was 71.4%. The test strip
accuracy was 89.1%.
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Fig. 3. The fecal pH (presented as the mean with 95% CI) as determined with the
test strip and the 1-month mortality (%) in each group of patients with diarrhea. The
Kruskal–Wallis and Mann–Whitney U-tests were performed to statistically analyze
the pH data, and the chi-square test was used to analyze mortality data.
****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05.
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has shown that of the cytokines (HGF, transforming growth factor-
a, transforming growth factor-b, and keratinocyte growth factor),
HGF is the most potent in terms of accelerating the repair of the
damaged monolayer of epithelial cells derived from normal rat
small intestine.
This study evaluated the ability of a new strip test to determine
the binding afﬁnity of acute phase proteins such as HGF to DS as a
tool for assessing patients with diarrhea. This strip test showed
high sensitivity and speciﬁcity for identifying infectious gastroen-
teritis in patients with diarrhea upon hospital admission.
The binding of HGF to HSPG on the cell surface and in the extra-
cellular matrix plays an important role in activating an HGF pre-
cursor and in facilitating its interaction with the high-afﬁnity
c-met receptor [35]. We observed previously that binding of HGF
to both high afﬁnity (c-Met) and low afﬁnity (HSPG) receptors
can be studied using a surface plasmon resonance-based system
to differentiate HGF that is biologically active during acute inﬂam-
mation from HGF that is present during chronic inﬂammatory dis-
eases [36]. We showed that unlike the biologically inactive form of
HGF, the biologically active form of HGF has binding afﬁnity to
HSPG [22], and this afﬁnity decreases signiﬁcantly when DS is
added to the samples. Thus, DS has properties similar to those of
HSPG in terms of binding to active HGF [20]. In a previous study,
we prepared a DS-containing gel and immobilized it on plastic
loops. Notably, DS changes the color of methylene from blue to
red, so we developed a method that took advantage of thisproperty. In this method, the binding of HGF to DS competes with
the interaction of DS and methylene blue and inhibits the color
change to red. Using this method, we tested fecal samples from
patients and healthy volunteers to investigate the ability of the
method to distinguish infectious gastroenteritis with high sensitiv-
ity and speciﬁcity [27]. We then developed this strip test based on
the binding afﬁnity of active HGF to DS.
Determination of fecal pH yields important information about
ion exchange in the bowel [37] and has been used as a non-speciﬁc
way to diagnose some bowel infections. This method was recently
demonstrated to predict outcome in severely ill patients [28]. Since
patients with generalized inﬂammatory response, or SIRS in the
course of severe trauma and/or sepsis, have HGF with high afﬁnity
to DS [27] and have high fecal pH [20], we determined both the
binding afﬁnity of HGF to DS and fecal pH. We observed that
patients with infectious gastroenteritis had higher fecal pH (pH
7.0–8.0) than those with non-infectious diarrhea (pH 5.0–6.0;
Fig. 3) and healthy controls (data not shown). However, fecal
pHP 9.0 was seen in cases with severe colitis and SIRS, and this
was associated with signiﬁcantly increased mortality (Fig. 3). Thus,
including a pH sensor in the strip test may differentiate cases with
self-limiting infectious gastroenteritis from cases at risk of bacte-
rial translocation, septicemia, and SIRS. This would mean that anti-
biotics could be used in a more directed way. Fecal pH 6 4.0
predicted an unfavorable outcome (data not shown).
Routine diagnostic tests for identifying infectious gastroenteri-
tis have low sensitivity (45.1%) [38]. We observed that the refer-
ence test for detecting the C. difﬁcile toxin in feces identiﬁed
cases with C. difﬁcile enteritis with a sensitivity of 66.6%. However,
technical improvements and the development of new diagnostic
methods have made diagnosis more rapid and accurate.
During the development of the strip test, we assessed the con-
centration of HGF in feces by ELISA. We observed previously that
the HGF concentration is signiﬁcantly higher in feces during infec-
tious gastroenteritis than in feces from diarrhea due to non-infec-
tious causes [18]. Additional studies showed that the concentration
of HGF in feces was signiﬁcantly higher in chronic IBD compared to
infectious gastroenteritis [20]. It is complicated to perform ELISAs
on stool samples [30], and it was not possible to perform ELISAs on
fresh samples. The strip test was developed based on the afﬁnity of
HGF to the receptor (HSPG) and not the concentration of HGF [26].
Thus, the concentration of HGF was determined in some samples,
and the stool samples that were negative for HGF on the strip test
included samples from cases with IBD as well as with other causes
of diarrhea (Table 1). Therefore the data was not normally distrib-
uted (Table 3).
Limitations: the strip test could not differentiate between the
various etiologies of infectious gastroenteritis. However, patient
isolation and avoiding antibiotic treatment are common manage-
ment strategies for infectious gastroenteritis. Difﬁculty in detect-
ing changes in the color is another limitation of the strip test,
and one that could be overcome by instrumentation. The
performance of the strip test did not change signiﬁcantly when
Table 3
Results from ELISA determination of the hepatocyte growth factor (HGF) concentration in stool samples from patients with diarrhea (n = 101).
Strip test result Elisa ng/ml range (median) p < 0.01 Veriﬁed infection bacterial or viral Veriﬁed non-infectious diarrhea
Positive (n = 49) 0.02–77.2 (0.93) 37 2
Negative (n = 52) 0.02-64.3 (0.47) 5 41
14 A.E. Sorour et al. / Cytokine 71 (2015) 8–15freeze-thawed feces were tested (data not shown) [30]. The bind-
ing afﬁnity to sulfated glycans/HSPG may not be limited to HGF
in feces i.e. there may be competitive binding by other proteins
as well. Although the strip test showed high sensitivity and speci-
ﬁcity in the current investigation, the lack of a gold standard for
comparison is a major limitation of this study.
Further studies are planned to further assess the performance of
the strip test and its possible impact on antibiotic use in different
patient groups and diseases.
5. Conclusions
In summary, HGF is a good local acute phase response marker
for acute bowel inﬂammation. We developed a new rapid test for
stool specimens that evaluates local production of HGF as a local
acute phase response marker in the bowel. We suggest that this
method can be used for the simultaneous determination of fecal
pH and the binding afﬁnity of fecal HGF to DS in order to assess
patients with symptoms of acute diarrhea. The strip test provides
useful information for making decisions about patient isolation
and for planning appropriate diagnostic procedures and therapy.
More data is needed before a test built on this platform can com-
plement or replace currently available tests.
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